Stories about therapy

Subscribe to therapy

05.11.2020 – 16:06

Novo Nordisk A/S
Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy

Bagsværd, Denmark (ots/PRNewswire) - Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.[i] The STEP 3 phase 3a trial investigated ...

more
02.10.2020 – 11:33

OD-OS GmbH
Euretina: OD-OS presents Navilas® Pro as an affordable entry to the digital ecosystem of navigated laser

Teltow (ots) - Navilas® Pro offers precise and fast treatments of common retinal diseases based on the unique digital workflow of navigated laser treatments - with DICOM upgrade and more At the first virtual EURETINA Congress, OD-OS presents its affordable entry to the digital ecosystem of navigated retinal laser ...

more
02.10.2020 – 09:31

Stada Arzneimittel
STADA expands specialty footprint through acquisition of innovative therapy for treating advanced Parkinson's disease

Press release STADA expands specialty footprint through acquisition of innovative therapy for treating advanced Parkinson’s disease - STADA is submitting approval applications to launch the new therapy in major European markets. Approvals are ...
One document
more
01.10.2020 – 14:00

Debiopharm International SA
DEBIOPHARM LAUNCHES TRILYNX - A LARGE-SCALE PHASE III CLINICAL TRIAL TO FURTHER EVALUATE XEVINAPANT IN THE TREATMENT OF HEAD & NECK CANCER

Lausanne, Switzerland (ots) - First patient dosed in the randomized, placebo-controlled Phase III study of xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) Debiopharm (www.debiopharm.com), a ...

more
27.08.2020 – 12:00

Sysmex Inostics GmbH
Sysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy

Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating RAS mutation status in circulating tumor DNA (ctDNA) of colorectal cancer (CRC) patients undergoing anti-EGFR ...

more
05.08.2020 – 12:18

Sysmex Inostics GmbH
Sysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing

Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care ...

more
09.06.2020 – 14:00

Debiopharm International SA
Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer

[Ort] (ots) - Debiopharm, a Swiss-based, biopharmaceutical company, and Verity Pharmaceuticals Inc., a US based specialty pharmaceutical company focused on therapeutic solutions for genitourinary (GU) diseases, today announced having entered into an exclusive agreement that grants Verity Pharmaceuticals Inc., in the ...

more
04.06.2020 – 13:20

Else Kröner-Fresenius-Stiftung

Groundbreaking Gene Therapies for Hereditary Diseases / Alessandro Aiuti, a physician and research scientist from Milan, receives the Else Kröner Fresenius Prize for Medical Research 2020 endowed with 2.5 million euros

more
26.03.2020 – 18:22

Elastrin Therapeutics
Elastrin Therapeutics develops new approach against "Inflammatory Storm" that kills most Corona patients

Greenville South Carolina (ots) - A previously untested approach to preventing the most severe outcomes of lung diseases, including COVID-19, has been developed by Elastrin Therapeutics based on targeting damaged elastic fiber that leads to impaired lung function. The company has developed the world's first ...

more
30.09.2019 – 10:40

QUANTIC NANOTECH
First Digital Health Osteoarthritis Wearable Glove System Starts Pre-launch Pilot Trial Series & Medical Tests

Madrid (ots/PRNewswire) - QUANTIC NANOTECH, a product division of Spanish DEMAC S.A. group who presented the first home wearable osteoarthritis treatment glove system "QNANO GLOVE" during the last CES 2019 Edition in Las Vegas, announced today the opening of free treatment sign-up registration for a new medical ...

more
19.03.2019 – 23:47

Merck KGaA
Merck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...

more
26.11.2018 – 10:01

Kyowa Kirin International PLC
Kyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome

Tokyo (ots/PRNewswire) - POTELIGEO will be the first biologic agent targeting CCR4 to be available for patients in Europe. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that it has received a European Commission decision granting a marketing authorisation to POTELIGEO® (Generic name: mogamulizumab), a ...

more
25.10.2018 – 13:34

Helmholtz Zentrum München
Two-pronged approach - Novel combined therapy tackles excess fatty tissue

A new combined therapy for obesity and diabetes has been shown to suppress the appetite and at the same time increase energy expenditure. Scientists from the Helmholtz Zentrum München and the Technical University of Munich (TUM), partner institutions of the German Center for ...
Online Version

more
18.10.2018 – 09:32

Technische Universität München
Test predicts outcome of hay fever therapies

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22731 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35000/ NEWS RELEASE Test predicts outcome of hay fever therapies Allergy researchers look into molecular processes in hyposensitization to pollen Allergen-specific immunotherapy can make everyday life ...

more
17.10.2018 – 13:31

Accuray
Accuray Showcases Radiation Therapy Innovations Designed to Improve What's Possible for Patients at ASTRO 2018

Sunnyvale, California (ots/PRNewswire) - Building on its heritage of patient-first innovation, at this year's ASTRO (American Society for Radiation Oncology) Annual Meeting, Accuray Incorporated (NASDAQ: ARAY) will showcase radiation therapy solutions designed to enable clinicians to deliver truly personalized ...

more
15.10.2018 – 13:06

Sysmex Inostics GmbH
Sysmex Inostics' OncoBEAM(TM) liquid biopsy technology demonstrates utility for clinical management of melanoma patients undergoing treatment with targeted therapy and immune checkpoint inhibitors

Hamburg, Germany (ots) - Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to ...

more
08.08.2018 – 18:40

Kyowa Kirin International PLC
Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

Tokyo (ots/PRNewswire) - - Poteligeo has been approved for the treatment of the two most common types of Cutaneous T-cell lymphoma (CTCL) in previously treated patients based on data showing improved progression-free survival (PFS) and overall response rate (ORR) when compared to vorinostat. - FDA approval was based ...

more
29.06.2018 – 01:02

Astellas Pharma Europe Limited
Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...

more
24.02.2012 – 08:55

Astellas Pharma Europe Limited
New Class of Treatment for Overactive Bladder Demonstrates Efficacy and Tolerability Across Three Separate Studies

Paris (ots/PRNewswire) - ASTELLAS PHARMA EUROPE Ltd., European subsidiary of Tokyo-based Astellas Pharma Inc. today announced results from three separate clinical trials that further support the efficacy and tolerability of mirabegron. Mirabegron, a beta3 adrenoceptor agonist, is the first in a new class of ...

more

1